• Oxaliplatin in Tumor Microenvironment Modeling: From Plat...

  2025-10-03

  Explore how Oxaliplatin, a platinum-based chemotherapeutic agent, drives innovative preclinical cancer research by enabling physiologically relevant tumor microenvironment models. This article uniquely focuses on integrating Oxaliplatin into advanced assembloid systems for personalized therapy optimization.

• Oxaliplatin: Unveiling Tumor Microenvironment Interaction...

  2025-10-02

  Explore the multifaceted role of Oxaliplatin in cancer chemotherapy, focusing on its platinum-based DNA adduct formation and apoptosis induction within sophisticated tumor microenvironment models. This article delivers unique insights into how stromal interactions and assembloid systems reshape chemotherapeutic strategies.

• Oxaliplatin in Patient-Specific Tumor Assembloids: Next-G...

  2025-10-01

  Explore how Oxaliplatin, a platinum-based chemotherapeutic agent, is revolutionizing cancer chemotherapy through its unique DNA adduct formation and integration into patient-derived tumor assembloids. Uncover advanced applications and translational insights not found in conventional tumor modeling.

• PD0325901: Selective MEK Inhibitor for Advanced Cancer Re...

  2025-09-30

  PD0325901 stands at the intersection of precision oncology and mechanistic research, enabling robust inhibition of the RAS/RAF/MEK/ERK pathway. Its unique capability to induce apoptosis, enforce cell cycle arrest, and modulate telomerase regulation makes it an indispensable tool for dissecting cancer cell fate and DNA repair dynamics.

• PD0325901: Unveiling MEK Inhibition for TERT Regulation a...

  2025-09-29

  Discover how PD0325901, a potent MEK inhibitor, uniquely illuminates the interplay between RAS/RAF/MEK/ERK pathway inhibition and TERT gene regulation in cancer research. Gain advanced insight into apoptosis induction, cell cycle arrest, and the future of targeted oncology.

• PD0325901: Targeting MEK-Driven Cancer via Telomerase and...

  2025-09-28

  Discover how PD0325901, a selective MEK inhibitor, uniquely connects RAS/RAF/MEK/ERK pathway inhibition with telomerase regulation and DNA repair in cancer research. Explore advanced mechanistic insights and translational opportunities that set this analysis apart.

• PD0325901 and MEK Inhibition: Unraveling Cancer Cell Fate...

  2025-09-27

  Explore how PD0325901, a selective MEK inhibitor, drives cancer research by connecting RAS/RAF/MEK/ERK pathway inhibition with telomerase regulation and DNA repair. Discover novel insights into apoptosis induction and tumor suppression that go beyond conventional analyses.

• Asunaprevir (BMS-650032): Systems Biology Insights into H...

  2025-09-26

  Explore the systems biology of Asunaprevir (BMS-650032), a potent HCV NS3 protease inhibitor, with a focus on its integrated impact on viral replication, host signaling (including caspase pathways), and hepatotropic drug distribution. This article uniquely synthesizes mechanistic, cellular, and translational insights for advanced hepatitis C virus research.

• ARCA EGFP mRNA: Unveiling the Gold Standard for Quantitat...

  2025-09-25

  Explore the scientific advantages of ARCA EGFP mRNA as a direct-detection reporter mRNA for quantitative mammalian cell gene expression studies. This in-depth article reveals how co-transcriptional capping with ARCA and Cap 0 structure uniquely enhance mRNA stability, delivery, and assay reliability.

• NHS-Biotin: Enabling Precision Biotinylation for Multimer...

  2025-09-24

  Discover how NHS-Biotin, an advanced amine-reactive biotinylation reagent, uniquely empowers the construction and study of multimeric and multispecific proteins. This article explores cutting-edge intracellular protein labeling strategies and offers scientific insights beyond standard protocols.

• Enhancing RNA Probe Labeling: Insights from HyperScribe T...

  2025-09-23

  Explore how the HyperScribe T7 High Yield Cy5 RNA Labeling Kit advances in vitro transcription RNA labeling for high-sensitivity applications. This article offers new perspectives on probe optimization, fluorescent nucleotide incorporation, and integration with emerging mRNA delivery strategies.

• Similarly compound was prepared from aldehyde d

  2025-03-03

  

  Similarly, FDA-approved Drug Library 13 was prepared from aldehyde 8d by following similar procedures (Scheme 3). Condensation of 13 with 7b or 7e provided the corresponding amides 9j or 9k, which then went through O-debenzylation by BCl3 to deliver the final compounds 10j and 10k in 37% and 32% ove

• br Author contributions br Funding This

  2025-03-03

  

  Author contributions Funding This work was supported by the Czech Science Foundation, project no. 14-16220S. Additional support was provided by NIH R01CA117907 grant awarded to J.M.E. Conflict of interest Introduction The dioxin-like family includes polyhalogenated aromatic hydrocarbons

• br Transparency document br Introduction G

  2025-03-03

  

  Transparency document Introduction G protein-coupled receptors (GPCRs) comprise a diverse family of seven transmembrane domain-containing receptors represented by over 800 genes in humans. GPCRs respond to a range of stimuli, including peptides, hormones, growth factors, lipids, odorants, and

• br Methods br Results br Discussion br Acknowledgements

  2025-03-03

  

  Methods Results Discussion Acknowledgements This work was supported by the National Institutes of Health [Grant R21 NS081429], a Pilot Grant from the Vanderbilt Conte Center supported by the National Institutes of Health [Grant P50 M096972], and by the Department of Anesthesiology at V

16771 records 9/1119 page Previous Next First page 上5页 678910 下5页 Last page